Dingli obtained Huawei Hisilicon 5G chip ICD authorization

Dingli reacted to financial specialists’ inquiries on the Shenzhen Stock Exchange’s Interactive Exchange on March 4, saying that the organization had acquired Huawei Hisilicon 5G chip ICD approval, and dependent on Huawei Hisilicon 5G chip terminals, it has progressively evolved and propelled 5G related test instruments.

Dingli is one of the largest mobile network test and measurement solution providers, covering 63 countries and regions across the globe. We are also one of the largest mobile network service providers in Mainland China, with nearly 300 ongoing network test and optimization projects spanning over 31 provinces, regions, and municipalities.

Likewise, the organization’s innovative work-related items for 5G arrange estimation completely support Qualcomm and Hisilicon 5G test terminals and have progressively gotten important requests for 5G items.

Dingli says it will always support Huawei and the roadmap of related products. The company will keep its focus on products that support the Hongmeng system.

Earlier, Dingli released the 2019 annual performance report and mentioned the company’s total income was 1.248 billion yuan, an increase of 26.95% over the same period last year; operating profit was -439 million.

The total profit was -4.62 yuan, a decrease of 938.66% over the same period last year; the net profit attributable to shareholders of listed companies was -483 million yuan, a decrease of 952.33% over the same period last year; basic per share Loss of 0.89 yuan.

Source